TB 181-36
Alternative Names: TB181-36Latest Information Update: 04 Dec 2020
At a glance
- Originator Twist Bioscience
- Developer Twist Bioscience; Vanderbilt University Medical Center
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 01 Nov 2020 Preclinical trials in COVID-2019 infections in USA (Parenteral)